<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00002033</url>
  </required_header>
  <id_info>
    <org_study_id>045A</org_study_id>
    <secondary_id>753A-202-BR,MX</secondary_id>
    <nct_id>NCT00002033</nct_id>
  </id_info>
  <brief_title>A Third-Party Blinded, Placebo Controlled Comparative Study of AS-101 Administered Intravenously in HIV Positive Patients With Advanced Disease</brief_title>
  <official_title>A Third-Party Blinded, Placebo Controlled Comparative Study of AS-101 Administered Intravenously in HIV Positive Patients With Advanced Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Wyeth is now a wholly owned subsidiary of Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>NIH AIDS Clinical Trials Information Service</source>
  <brief_summary>
    <textblock>
      To compare the effect of AS-101 to that of placebo on clinical efficacy and immunologic&#xD;
      function in HIV positive patients with advanced disease. To compare the effect of AS-101 to&#xD;
      that of placebo on occurrence of disease progression in HIV positive patients with advanced&#xD;
      disease as defined by: (1) development of new diagnostically confirmed major opportunistic&#xD;
      infection(s); or (2) development of AIDS-related dementia. To compare the effect of&#xD;
      zidovudine (AZT) plus AS-101 versus AZT alone (placebo arm) on clinical efficacy and&#xD;
      immunologic function in patients who require anti-viral therapy due to disease progression.&#xD;
      Garlic capsules will be given to all study participants to mask the obvious garlic odor of&#xD;
      AS-101.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <condition>HIV Infections</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Zidovudine</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AS-101</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
        Concurrent Medication:&#xD;
&#xD;
        Allowed:&#xD;
&#xD;
          -  Standard therapy including acyclovir or ganciclovir for infections that develop during&#xD;
             the study period. (Prophylactic acyclovir is not permitted.) Standard therapy for&#xD;
             persistent infections may continue.&#xD;
&#xD;
          -  Immunomodulators or specific therapy for malignancies (including Kaposi's sarcoma)&#xD;
             allowed only with permission of Wyeth-Ayerst medical monitor.&#xD;
&#xD;
          -  Zidovudine (AZT) may be added only if there is disease progression and after the&#xD;
             patient has been in the study for a minimum of eight weeks.&#xD;
&#xD;
          -  Garlic capsules will be given to all study participants to mask side effects of&#xD;
             AS-101.&#xD;
&#xD;
          -  Required:&#xD;
&#xD;
          -  Accepted standard prophylaxis for patients with prior Pneumocystis carinii pneumonia&#xD;
             (PCP).&#xD;
&#xD;
        Patients must have the following:&#xD;
&#xD;
          -  Diagnosis of AIDS or AIDS-related complex (ARC).&#xD;
&#xD;
          -  Life expectancy &gt; 6 months.&#xD;
&#xD;
          -  Provide written informed consent.&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
        Co-existing Condition:&#xD;
&#xD;
        Patients with the following conditions or symptoms are excluded:&#xD;
&#xD;
          -  Evidence of severe liver dysfunction (serum albumin &lt; 2.5 g/dl, prothrombin time &gt; 15&#xD;
             seconds or SGOT or SGPT &gt; 3 x upper limits of normal), gastrointestinal, renal,&#xD;
             respiratory, endocrine, hematologic, cardiovascular system abnormalities or&#xD;
             psychiatric disorders which would prevent compliance with the protocol.&#xD;
&#xD;
          -  Evidence of AIDS related dementia.&#xD;
&#xD;
          -  Presence of disseminated Kaposi's sarcoma defined as any visceral lesions or &gt; 20&#xD;
             cutaneous lesions; or Kaposi's sarcoma without at least one other AIDS defining&#xD;
             characteristic.&#xD;
&#xD;
          -  Presence of any lymphoma.&#xD;
&#xD;
          -  Active opportunistic infection currently requiring treatment unless the infection has&#xD;
             stabilized and continuing treatment is only required to prevent relapse (e.g., CNS&#xD;
             toxoplasmosis or resolving tuberculosis).&#xD;
&#xD;
        Concurrent Medication:&#xD;
&#xD;
        Excluded:&#xD;
&#xD;
          -  Prophylactic acyclovir.&#xD;
&#xD;
          -  Immunomodulators or specific therapy for malignancies (including Kaposi's sarcoma)&#xD;
             allowed only with permission of Wyeth-Ayerst medical monitor.&#xD;
&#xD;
          -  Zidovudine (AZT) may be added only if there is disease progression and after the&#xD;
             patient has been in the study for a minimum of eight weeks.&#xD;
&#xD;
        Patients with the following are excluded:&#xD;
&#xD;
          -  Evidence of severe organ dysfunction as defined in Exclusion complications or other&#xD;
             specified disease conditions.&#xD;
&#xD;
          -  Unlikely or unable to comply with the requirements of the protocol.&#xD;
&#xD;
        Prior Medication:&#xD;
&#xD;
        Excluded within 8 weeks of study entry:&#xD;
&#xD;
          -  Any immune stimulation agents such as BCG vaccine, interferons, or other immune&#xD;
             modulators within 8 weeks.&#xD;
&#xD;
          -  Any immunosuppressive agent within 8 weeks.&#xD;
&#xD;
          -  Excluded within 12 weeks of study entry:&#xD;
&#xD;
          -  Zidovudine (AZT).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>13 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Escola Paulista De-Medicina</name>
      <address>
        <city>Sao Paulo</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Faculdade De-Ciencias Medica Da</name>
      <address>
        <city>Sao Paulo</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hosp De-Servidor Publico Estadual</name>
      <address>
        <city>Sao Paulo</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto Do Cancer Arnaldo Vieiro</name>
      <address>
        <city>Sao Paulo</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <reference>
    <citation>Amarante JM, Levi GC, Pedro RJ, Galvao PA, Scheinberg M, Levy DS. A double blind controlled study with AS-101 in patients infected with HIV. Int Conf AIDS. 1992 Jul 19-24;8(2):B160 (abstract no PoB 3439)</citation>
  </reference>
  <verification_date>February 1991</verification_date>
  <study_first_submitted>November 2, 1999</study_first_submitted>
  <study_first_submitted_qc>August 30, 2001</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 31, 2001</study_first_posted>
  <last_update_submitted>June 23, 2005</last_update_submitted>
  <last_update_submitted_qc>June 23, 2005</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 24, 2005</last_update_posted>
  <keyword>Acquired Immunodeficiency Syndrome</keyword>
  <keyword>AIDS-Related Complex</keyword>
  <keyword>ammonium trichloro(dioxoethylene-O,O'-)tellurute</keyword>
  <keyword>Zidovudine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
    <mesh_term>HIV Seropositivity</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Zidovudine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

